Allakos Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 131
- Market Cap
- $62.1M
- Website
- http://www.allakos.com
Clinical Trials
30
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: AK006 IV
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT06577116
- Locations
- 🇺🇸
Site 601-004, Birmingham, Alabama, United States
🇺🇸Site 601-014, Bakersfield, California, United States
🇺🇸Site 601-015, Upland, California, United States
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
- Conditions
- Healthy ParticipantsChronic Spontaneous Urticaria
- Interventions
- Drug: AK006-IVDrug: AK006-SCDrug: Placebo-IVDrug: Placebo-SC
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT06072157
- Locations
- 🇺🇸
Site 601-001 Healthy Volunteer Clinical Research Unit (Part A, B and D), Anniston, Alabama, United States
🇺🇸Site 601-004 (Part C), Birmingham, Alabama, United States
🇺🇸Site 601-008 (Part C), Scottsdale, Arizona, United States
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Other: Placebo
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT05528861
- Locations
- 🇺🇸
Allakos Investigational Site 227-024, Birmingham, Alabama, United States
🇺🇸Allakos Investigational Site 227-068, Cullman, Alabama, United States
🇺🇸Allakos Investigational Site 227-014, Phoenix, Arizona, United States
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT05155085
- Locations
- 🇺🇸
Allakos Investigational Site 218-034, Birmingham, Alabama, United States
🇺🇸Allakos Investigational Site 218-074, Cullman, Alabama, United States
🇺🇸Allakos Investigational Site 218-025, Gilbert, Arizona, United States
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
- Conditions
- Eosinophilic GastritisEosinophilic Duodenitis
- Interventions
- Other: Placebo
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Allakos Inc.
- Registration Number
- NCT05152563
- Locations
- 🇺🇸
Allakos Investigational Site, Seattle, Washington, United States
- Prev
- 1
- 2
- 3
- 4
- Next